Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
The FDA has approved daraxonrasib, marketed as Rasonque by Revolution Medicines, for the treatment of metastatic pancreatic cancer. Early clinical data now suggests the drug may also be effective for patients with metastatic non-small cell lung cancer, specifically those with RAS-mutant tumors. The New England Journal of Medicine recently published Phase 1/2 clinical data supporting this potential application. While initially developed for pancreatic cancer, these early results indicate the targeted therapy could expand its utility to treat other RAS-driven malignancies.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The FDA approved daraxonrasib for metastatic pancreatic cancer.
- ✓ Revolution Medicines markets the drug under the name Rasonque.
- ✓ Phase 1/2 clinical data for the drug in metastatic non-small cell lung cancer was published in the New England Journal of Medicine.
- ✓ Daraxonrasib has demonstrated initial antitumor activity in RAS-mutant lung cancer.
What changed
The New England Journal of Medicine published Phase 1/2 clinical data on daraxonrasib for metastatic non-small cell lung cancer.
Live updates
-
FDA-approved pancreatic cancer drug shows promise for lung cancer
The FDA has approved daraxonrasib, marketed as Rasonque by Revolution Medicines, for the treatment of metastatic pancreatic cancer. Early clinical data now suggests the drug may also be effective for patients with metastatic non-small cell lung cancer, specifically those with RAS-mutant tumors. The New England Journal of Medicine recently published Phase 1/2 clinical data supporting this potential application. While initially developed for pancreatic cancer, these early results indicate the targeted therapy could expand its utility to treat other RAS-driven malignancies.
Why it matters
RAS mutations are common drivers in several aggressive cancers. Finding a single targeted therapy that works across different organ types could simplify treatment for metastatic patients. The drug's approval for pancreatic cancer followed a landmark trial led by Dana-Farber.
What is confirmed
- The FDA approved daraxonrasib for metastatic pancreatic cancer.
- Revolution Medicines markets the drug under the name Rasonque.
- Phase 1/2 clinical data for the drug in metastatic non-small cell lung cancer was published in the New England Journal of Medicine.
- Daraxonrasib has demonstrated initial antitumor activity in RAS-mutant lung cancer.
Still unconfirmed
- A cancer pill costs $480,000 a year.
What to watch next
- Results from larger Phase 2 or Phase 3 clinical trials for lung cancer applications.
- FDA decision on expanding the approved indication of daraxonrasib to include non-small cell lung cancer.
confidence 95%Sources used for this update (9)
- The New York Times — A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
- ABC News - Breaking News, Latest News and Videos — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
- Yahoo Finance — New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
- News-Medical — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
- NBC News — Newly approved pancreatic cancer drug shows promise in lung cancer
- BioSpace — RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
- Portland Press Herald - Maine Sunday Telegram — New pancreatic cancer drug gives South Portland man hope for longer life
- Newswise — Daraxonrasib Demonstrates Initial Antitumor Activity in RAS-Mutant Lung Cancer | Newswise
- www.yahoo.com — Breakthrough Pancreatic Cancer Drug Shows Promise In Lung Cancer Trial
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community